ArticleMolecular biology reports2026
Stem-like characteristics across sequentially temozolomide-adapted glioblastoma cell populations with increasing levels of acquired resistance.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAcquired temozolomide (TMZ) resistance remains a major challenge in glioblastoma and may involve the emergence or enrichment of cancer stem cell (CSC)-like characteristics. However, whether stem-like characteristics differ across increasing levels of acquired TMZ resistance remains unclear. This study compared stem-like characteristics among parental TMZ-sensitive glioblastoma cells and two sequentially generated TMZ-adapted populations with different levels of acquired TMZ resistance. METHODS AND
resultsTwo TMZ-adapted glioblastoma cell populations (U87MG-T5 and U87MG-T67) were established through sequential TMZ exposure of parental U87MG cells. TMZ sensitivity was assessed by determining CC50 values, whereas proliferation was evaluated using population doubling time and viable cell counts. The mRNA expression levels of the aggressiveness-associated genes, vimentin and MMP2, were examined by qRT-PCR. Stem-like characteristics were assessed by measuring spheroid-forming capacity, sphere-initiating cell frequency, CD133 surface expression, and expression of OCT4 and SOX2. Both U87MG-T5 and U87MG-T67 exhibited lower TMZ sensitivity and slower proliferation than U87MG cells, with the most pronounced changes in U87MG-T67. Vimentin and MMP2 mRNA expressions were significantly higher in U87MG-T67, but not in U87MG-T5. Both adapted populations exhibited enhanced spheroid-forming capacity, increased sphere-initiating cell frequency, and higher proportion of CD133 positive cells than TMZ-sensitive cells. SOX2 mRNA expression was upregulated in U87MG-T5, whereas OCT4 mRNA expression was upregulated in U87MG-T67. Descriptive Western blot analysis showed that the SOX2 and OCT4 protein expressions appeared to be highest U87MG-T67.
conclusionsBoth U87MG-T5 and U87MG-T67 showed more pronounced CSC-like characteristics than parental U87MG cells, although they showed different patterns of SOX2 and OCT4 mRNA expression.
Indexed as
Identifiers
42579188What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.